As part of its reporting of the second quarter and the first half of 2023 financial results, Pharming indicated that underlying in-market demand for RUCONEST® in the U.S. continues to be strong. Pharming reported having received over 70 new patient enrollments in each quarter of 2023. The company concludes that this underpins the importance of RUCONEST® to HAE patients, including those patients on prophylaxis who should have medication on hand to treat any breakthrough attacks.
Chief Executive Officer, Sijmen de Vries, commented: “The second quarter of 2023 was strong for Pharming. After the reimbursement disruptions experienced in the HAE market in the first quarter, RUCONEST® recovered significantly in the second quarter, increasing 20% over the first quarter of 2023. Our RUCONEST® business performed well across a variety of leading revenue indicators, positioning us well for the second half of the year. RUCONEST® continues to provide a stable base for Pharming’s future growth, and we continue to foresee low single-digit growth in sales for the year.”
RUCONEST® is marketed for the treatment of acute HAE attacks.
(Source: Pharming Group)
